U.S. Supreme Court ruling on generic drugs

According to the new ruling from the U.S. Supreme Court, people harmed by generic drugs may find it harder to get restitution. The court ruled on Thursday that generic drug makers cannot be sued for failing to warn consumers of their products' side effects if they copy the exact warnings on the drugs' brand-name equivalents.

The decision was 5-4 and the court ruled that the federal law requiring generics to have the same warnings as their brand-name equivalents trumps state laws that allow people to sue drug companies that fail to provide proper warnings for their products.

Justice Sonia Sotomayor said in a dissent, “As a result of today's decision, whether a consumer harmed by inadequate warnings can obtain relief turns solely on the happenstance of whether her pharmacist filled her prescription with a brand-name or generic drug. The court gets one thing right: This outcome makes little sense.”

Justice Clarence Thomas added that it was impossible for generic drug makers to comply both with federal laws requiring them to have the same label as the brand-name drugs and state laws that require them to add additional warnings. So the federal law prevails. Thomas acknowledged the “unfortunate hand” dealt to people who are harmed by inadequate labels on generic drugs. They would be able to sue the companies who make brand name drugs for the same offense but are barred from suing the generic manufacturers.

This decision could affect millions of Americans, given that generics make up 75 percent of the prescription drugs dispensed in the U.S., justices said.

In the first case, Pliva v. Mensing, No. 09-993, the court split 5 to 4 along ideological lines in ruling that the makers of generic drugs may not be sued under state law for failing to warn customers about the risks associated with their products. Gladys Mensing and Julie Demahy had sued PLIVA Inc. and other generic drug manufacturers in state courts in Minnesota and Louisiana over the labels for metoclopramide, the generic version of Reglan. The two women alleged that metoclopramide gave them a severe neurological movement disorder called tardive dyskinesia, but none of the generic drug's manufacturers and distributors made any effort to include warnings on the label. PLIVA Inc. and other generic drug manufacturers argue that it's not their legal responsibility to request label changes, and that lawsuits filed in state courts over the content of labels improperly infringe on the Food and Drug Administration's enforcement area.

Dr. Ananya Mandal

Written by

Dr. Ananya Mandal

Dr. Ananya Mandal is a doctor by profession, lecturer by vocation and a medical writer by passion. She specialized in Clinical Pharmacology after her bachelor's (MBBS). For her, health communication is not just writing complicated reviews for professionals but making medical knowledge understandable and available to the general public as well.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Mandal, Ananya. (2018, August 23). U.S. Supreme Court ruling on generic drugs. News-Medical. Retrieved on June 16, 2024 from https://www.news-medical.net/news/20110623/US-Supreme-Court-ruling-on-generic-drugs.aspx.

  • MLA

    Mandal, Ananya. "U.S. Supreme Court ruling on generic drugs". News-Medical. 16 June 2024. <https://www.news-medical.net/news/20110623/US-Supreme-Court-ruling-on-generic-drugs.aspx>.

  • Chicago

    Mandal, Ananya. "U.S. Supreme Court ruling on generic drugs". News-Medical. https://www.news-medical.net/news/20110623/US-Supreme-Court-ruling-on-generic-drugs.aspx. (accessed June 16, 2024).

  • Harvard

    Mandal, Ananya. 2018. U.S. Supreme Court ruling on generic drugs. News-Medical, viewed 16 June 2024, https://www.news-medical.net/news/20110623/US-Supreme-Court-ruling-on-generic-drugs.aspx.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Genetic discovery reveals key to inflammatory diseases